ZimVie (NASDAQ:ZIMV) Updates FY 2024 Earnings Guidance

ZimVie (NASDAQ:ZIMV) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.550-0.700 for the period, compared to the consensus earnings per share estimate of 0.100. The company issued revenue guidance of $450.0 million-$460.0 million, compared to the consensus revenue estimate of $454.1 million.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ZIMV shares. Needham & Company LLC reaffirmed a hold rating on shares of ZimVie in a research note on Thursday, April 11th. Barclays raised their price target on ZimVie from $13.00 to $16.00 and gave the stock an underweight rating in a research note on Tuesday, March 5th.

ZimVie Stock Performance

Shares of NASDAQ ZIMV traded down $0.67 during midday trading on Wednesday, reaching $15.38. The company had a trading volume of 332,335 shares, compared to its average volume of 335,529. The business’s 50-day simple moving average is $16.48 and its 200 day simple moving average is $14.99. The stock has a market cap of $418.64 million, a P/E ratio of -1.04 and a beta of 2.17. ZimVie has a 1 year low of $6.52 and a 1 year high of $20.91. The company has a current ratio of 2.78, a quick ratio of 2.32 and a debt-to-equity ratio of 1.26.

ZimVie (NASDAQ:ZIMV) last issued its earnings results on Wednesday, February 28th. The company reported $0.10 earnings per share (EPS) for the quarter. ZimVie had a negative net margin of 51.33% and a positive return on equity of 2.44%. The firm had revenue of $113.07 million during the quarter.

ZimVie Company Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.